Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Webb

Showing results (201-210 of 204) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 204 results.
JCO Oncology Practice|March 6, 2025
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01)Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 5, 2023
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03Thomas M Atkinson, Shelly Lensing, Jeannette Y Lee, et al.
Pageof 21

Showing results (201-210 of 204) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 204 results.
JCO Oncology Practice|March 6, 2025
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01)Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 5, 2023
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03Thomas M Atkinson, Shelly Lensing, Jeannette Y Lee, et al.
Pageof 21